Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) shares saw an uptick in trading volume on Wednesday . 2,747,644 shares changed hands during mid-day trading, an increase of 196% from the previous session’s volume of 926,906 shares.The stock last traded at $1.67 and had previously closed at $1.46.

Separately, ValuEngine upgraded Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, June 15th.

The company’s market cap is $84.65 million. The stock has a 50-day moving average price of $1.18 and a 200 day moving average price of $1.64.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). During the same period in the previous year, the company posted $1.05 earnings per share. On average, equities analysts anticipate that Infinity Pharmaceuticals, Inc. will post ($0.92) earnings per share for the current fiscal year.

In other Infinity Pharmaceuticals news, insider Value Fund L. P. Biotechnology acquired 1,600,046 shares of Infinity Pharmaceuticals stock in a transaction dated Wednesday, October 4th. The stock was bought at an average cost of $1.26 per share, for a total transaction of $2,016,057.96. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.81% of the company’s stock.

Large investors have recently modified their holdings of the stock. Zacks Investment Management acquired a new stake in Infinity Pharmaceuticals in the 2nd quarter valued at about $101,000. Highbridge Capital Management LLC acquired a new stake in Infinity Pharmaceuticals in the 1st quarter valued at about $106,000. Ameriprise Financial Inc. acquired a new stake in Infinity Pharmaceuticals in the 2nd quarter valued at about $130,000. LMR Partners LLP acquired a new stake in Infinity Pharmaceuticals in the 2nd quarter valued at about $222,000. Finally, Wells Fargo & Company MN lifted its stake in Infinity Pharmaceuticals by 144.6% in the 1st quarter. Wells Fargo & Company MN now owns 81,493 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 48,177 shares during the last quarter. Institutional investors and hedge funds own 67.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.